Cover Image
市場調查報告書

類鐸受體4:開發中產品分析

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365746
出版日期 內容資訊 英文 119 Pages
訂單完成後即時交付
價格
Back to Top
類鐸受體4:開發中產品分析 Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2017
出版日期: 2017年07月25日 內容資訊: 英文 119 Pages
簡介

本報告提供以類鐸受體4為標的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

類鐸受體4 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 開發中的產品:各企業
  • 開發中的產品:各大學/機關

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AptaTargets SL
  • Batu Biologics Inc
  • Biomedica Management Corp
  • Eisai
  • eTheRNA Immunotherapies NV
  • EyeGene Inc
  • Formune SL
  • GlaxoSmithKline Plc
  • Harbor Therapeutics Inc
  • Immune Design Corp
  • Immunovo BV
  • 杏林藥業
  • NovImmune SA
  • Sanofi
  • TaiwanJ Pharmaceuticals Co Ltd
  • Vascular Biogenics Ltd

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0944TDB

Summary:

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).

Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 39 molecules. Out of which approximately 33 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 10, 3, 16 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Gastrointestinal, Immunology, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Dermatology, Ear Nose Throat Disorders, Mouth and Dental Disorders, Musculoskeletal Disorders, Ophthalmology and Other Diseases which include indications Pulmonary Inflammation, Breast Cancer, Inflammation, Inflammatory Bowel Disease, Liver Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Atherosclerosis, Autoimmune Hepatitis, Drug Addiction, Kidney Disease, Kidney Fibrosis, Rheumatoid Arthritis, Sepsis, Soft Tissue Sarcoma, Traumatic Brain Injury, Acne Vulgaris, Acute Ischemic Stroke, Acute Lung Injury, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Asthma, Atopic Dermatitis, Autoimmune Disorders, Bacterial Sepsis, Burns, Cervical Cancer, Crohn's Disease (Regional Enteritis), Ebolavirus Infections (Ebola Hemorrhagic Fever), Endotoxemia, Epilepsy, Escherichia coli Infections, Follicular Lymphoma, Globoid Cell Leukodystrophy (Krabbe Disease), Hearing Disorders, Hepatitis B, Hepatitis C, Hepatocellular Carcinoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus (HPV) Associated Cancer, Human Papillomavirus Infections, Ischemia Reperfusion Injury, Keratoconjunctivitis sicca (Dry Eye), Leishmaniasis (Kala-Azar), Listeriosis, Lung Cancer, Marburgvirus Infections (Marburg Hemorrhagic Fever), Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Multiple Sclerosis, Necrotizing Enterocolitis, Neuropathic Pain, Non Alcoholic Fatty Liver Disease (NAFLD), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Hodgkin Lymphoma, Opium Withdrawal Syndrome, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Peanut Allergy, Phlebovirus Infections, Post-Traumatic Stress Disorder (PTSD), Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Pseudomonas aeruginosa Infections, Recurrent Glioblastoma Multiforme (GBM), Rosacea, Secondary Progressive Multiple Sclerosis (SPMS), Septic Shock, Trauma, Wounds, Xerostomia and Zika Virus Infections.

The latest report Toll Like Receptor 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
  • The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview
    • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development
    • AptaTargets SL
    • Batu Biologics Inc
    • Biomedica Management Corp
    • Eisai Co Ltd
    • eTheRNA Immunotherapies NV
    • EyeGene Inc
    • Formune SL
    • GlaxoSmithKline Plc
    • Harbor Therapeutics Inc
    • Immune Design Corp
    • Immunovo BV
    • Kyorin Pharmaceutical Co Ltd
    • NovImmune SA
    • Sanofi
    • TaiwanJ Pharmaceuticals Co Ltd
    • Vascular Biogenics Ltd
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles
    • ApTOLL - Drug Profile
    • AyuV-25 - Drug Profile
    • Biologic to Agonize TLR4 for Drug Addiction - Drug Profile
    • C-34 - Drug Profile
    • CIA-05 - Drug Profile
    • CMB-305+G-100 - Drug Profile
    • CRX-526 - Drug Profile
    • DMT-210 - Drug Profile
    • Drugs to Agonize TLR4 for Oncology - Drug Profile
    • ECF-843 - Drug Profile
    • ECI-006 - Drug Profile
    • EDA-HPVE7 - Drug Profile
    • eritoran tetrasodium - Drug Profile
    • G-100 - Drug Profile
    • Glyco-23 - Drug Profile
    • GSK-1795091 - Drug Profile
    • HE-3286 - Drug Profile
    • hp-91 - Drug Profile
    • ibudilast - Drug Profile
    • ISAS-01 - Drug Profile
    • JKB-117 - Drug Profile
    • JKB-119 - Drug Profile
    • JKB-121 - Drug Profile
    • naltrexone hydrochloride - Drug Profile
    • NI-0101 - Drug Profile
    • P-13 - Drug Profile
    • P-16 - Drug Profile
    • P-7 - Drug Profile
    • P-MAPA - Drug Profile
    • PEPA-10 - Drug Profile
    • rabeximodum - Drug Profile
    • SAR-439794 - Drug Profile
    • Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
    • Small Molecules to Antagonize TLR2 and TLR4 for Immunology and Inflammation - Drug Profile
    • Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile
    • Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile
    • TWJ-201 - Drug Profile
    • VB-201 - Drug Profile
    • VB-703 - Drug Profile
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products
  • Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1)
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by AptaTargets SL, H2 2017
  • Pipeline by Batu Biologics Inc, H2 2017
  • Pipeline by Biomedica Management Corp, H2 2017
  • Pipeline by Eisai Co Ltd, H2 2017
  • Pipeline by eTheRNA Immunotherapies NV, H2 2017
  • Pipeline by EyeGene Inc, H2 2017
  • Pipeline by Formune SL, H2 2017
  • Pipeline by GlaxoSmithKline Plc, H2 2017
  • Pipeline by Harbor Therapeutics Inc, H2 2017
  • Pipeline by Immune Design Corp, H2 2017
  • Pipeline by Immunovo BV, H2 2017
  • Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
  • Pipeline by NovImmune SA, H2 2017
  • Pipeline by Sanofi, H2 2017
  • Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017
  • Pipeline by Vascular Biogenics Ltd, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top